Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 10/20 | 0.52 |
| ▸ | CACNA1H | O95180 | 10/20 | 0.52 |
| ▸ | CACNA1G | O43497 | 9/20 | 0.52 |
| ▸ | HTR6 | P50406 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17259263 | 0.86 | HTR6 (0.44) | KCNH2CACNA1HCACNA1GHTR6ALDH1A1 | |
| SCHEMBL4254538 | 0.82 | ALDH1A1 (0.41) | ALDH1A1GAAKDM4CLMNA | |
| SCHEMBL16249227 | 0.82 | KCNH2 (0.46) | KCNH2CACNA1HCACNA1GHTR6GAA | |
| SCHEMBL17259258 | 0.82 | KCNH2 (0.46) | KCNH2CACNA1HCACNA1GHTR6GAA | |
| SCHEMBL23402955 | 0.77 | KCNH2 (0.52) | KCNH2CACNA1HCACNA1GHTR6ALDH1A1 | |
| SCHEMBL16241332 | 0.77 | ALDH1A1 (0.55) | KCNH2CACNA1HCACNA1GHTR6ALDH1A1 | |
| SCHEMBL4704374 | 0.75 | TSHR (0.44) | CACNA1GALDH1A1GAAKDM4CLMNA | |
| SCHEMBL17259261 | 0.75 | KCNH2 (0.60) | KCNH2CACNA1HCACNA1GHTR6ALDH1A1 | |
| SCHEMBL3300740 | 0.75 | KCNH2 (0.60) | KCNH2CACNA1HCACNA1GHTR6ALDH1A1 | |
| SCHEMBL17259259 | 0.75 | KCNH2 (0.60) | KCNH2CACNA1HCACNA1GHTR6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493423-B2 | Compounds capable of inhibiting voltage gated calcium ion channel, and pharmaceutical compositions comprising the same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2016-11-15 | — | — | US | disclosed |
| US-20150329533-A1 | COMPOUNDS CAPABLE OF INHIBITING VOLTAGE GATED CALCIUM ION CHANNEL, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2015-11-19 | — | — | US | disclosed |
| US-8895602-B1 | 6-pyrazolylamido-3-substituted azabicyclo[3.1.0]hexane compounds as calcium channel inhibitors | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2014-11-25 | — | — | US | disclosed |
| US-8895602-B1 | 6-pyrazolylamido-3-substituted azabicyclo[3.1.0]hexane compounds as calcium channel inhibitors | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2014-11-25 | — | — | US | disclosed |
| US-8895602-B1 | 6-pyrazolylamido-3-substituted azabicyclo[3.1.0]hexane compounds as calcium channel inhibitors | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2014-11-25 | — | — | US | disclosed |
| US-20140343295-A1 | NOVEL 6-PYRAZOLYLAMIDO-3-SUBSTITUTED AZABICYCLO[3.1.0]HEXANE COMPOUNDS AS CALCIUM CHANNEL INHIBITORS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2014-11-20 | — | — | US | disclosed |
| US-20140343295-A1 | NOVEL 6-PYRAZOLYLAMIDO-3-SUBSTITUTED AZABICYCLO[3.1.0]HEXANE COMPOUNDS AS CALCIUM CHANNEL INHIBITORS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2014-11-20 | — | — | US | disclosed |
| US-20140343295-A1 | NOVEL 6-PYRAZOLYLAMIDO-3-SUBSTITUTED AZABICYCLO[3.1.0]HEXANE COMPOUNDS AS CALCIUM CHANNEL INHIBITORS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2014-11-20 | — | — | US | disclosed |
| US-8299072-B2 | Pyrazolylmethylamine compounds as calcium channel modulators and preparation method thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2012-10-30 | — | — | US | disclosed |
| US-8299072-B2 | Pyrazolylmethylamine compounds as calcium channel modulators and preparation method thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2012-10-30 | — | — | US | disclosed |
| US-8299072-B2 | Pyrazolylmethylamine compounds as calcium channel modulators and preparation method thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2012-10-30 | — | — | US | disclosed |
| US-20100094006-A1 | NOVEL PYRAZOLYLMETHYLAMINE COMPOUNDS AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2010-04-15 | — | — | US | disclosed |
| US-20100094006-A1 | NOVEL PYRAZOLYLMETHYLAMINE COMPOUNDS AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2010-04-15 | — | — | US | disclosed |
| US-20100094006-A1 | NOVEL PYRAZOLYLMETHYLAMINE COMPOUNDS AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2010-04-15 | — | — | US | disclosed |
| EP-1757590-B1 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | KOREA INST SCI & TECH (KR) | 2009-12-02 | — | — | EP | disclosed |
| US-7544686-B2 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2009-06-09 | — | — | US | disclosed |
| US-20070049604-A1 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2007-03-01 | — | — | US | disclosed |
| EP-1757590-A1 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | Korea Institute of Science and Technology (KR) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329533-A1 | COMPOUNDS CAPABLE OF INHIBITING VOLTAGE GATED CALCIUM ION CHANNEL, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CACNA1B, CACNA1F, CACNA1G | KCNH2 33/4885CACNA1H 9/4885CACNA1G 3/4885 |
| US-20140343295-A1 | NOVEL 6-PYRAZOLYLAMIDO-3-SUBSTITUTED AZABICYCLO[3.1.0]HEXANE COMPOUNDS AS CALCIUM CHANNEL INHIBITORS | CACNA1B, CACNA1I, CACNA1D | KCNH2 67/4885CACNA1H 8/4885CACNA1G 5/4885 |
| US-20070049604-A1 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | CACNA1I, CACNA1G, CACNA1H | KCNH2 31/4885CACNA1H 3/4885CACNA1G 2/4885 |
| US-20100094006-A1 | NOVEL PYRAZOLYLMETHYLAMINE COMPOUNDS AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF | CACNA1I, CACNA1C, ORAI1 | KCNH2 69/4885CACNA1H 11/4885CACNA1G 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.